Buy Boldenone Undecylenate 250 (Equipoise) – HilmaBioCare EU

Product Overview & Pharmaceutical Specifications

Boldenone Undecylenate 250 is an oily injectable formulation containing boldenone undecylenate as its active pharmaceutical ingredient. The supplied product information identifies the formulation as a sterile oil-based solution intended for intramuscular injection.

Product Specifications

• Product name: Boldenone Undecylenate 250
• Alternative name supplied: Equipoise
• Active pharmaceutical ingredient (API): Boldenone undecylenate
• Strength: 250 mg/ml
• Dosage form: Injectable, oil-based sterile solution
• Route of administration: Intramuscular (IM) injection
• Pack size: 10 ml
• Packaging: Multiple-dose vial
• CAS number: 13103-34-9
• Molecular formula: C30H40O3
• Molecular mass: 452.66856 g/mol
• Manufacturer/company: Hilma Biocare
• Market status supplied: Prescription
• Storage conditions: Store in a cool, dry place between 15–25°C. Protect from light.

Pharmaceutical Formulation

The supplied description identifies Boldenone Undecylenate 250 as an oily solution of boldenone undecylenate for IM injection.

The product documentation states that the formulation is designed to release boldenone slowly from the injection site, with boldenone serum levels described as remaining elevated for approximately 5–8 days after administration.

Pharmacology & Product Information

Pharmacological Class

Boldenone is described in the supplied documentation as an anabolic steroid possessing anabolic properties with moderate androgenic activity.

Anabolic steroids are synthetic derivatives of testosterone. Their pharmacological effects can include both anabolic and androgenic activity, and the supplied clinical pharmacology information notes that complete separation of these effects has not been achieved.

Mechanism of Action & Endocrine Effects

The supplied clinical pharmacology information states that anabolic steroids can suppress gonadotropic pituitary function and may exert direct effects upon the testes.

During exogenous administration of anabolic androgens, endogenous testosterone release may be inhibited through suppression of pituitary luteinizing hormone (LH). At larger doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).

These endocrine effects are relevant to the safety and monitoring considerations described in the supplied product information.

Pharmacological Context

The supplied information reports that pharmacological studies involving laboratory animals demonstrated boldenone to possess anabolic properties together with moderate androgenic activity.

The source also states that clinical trials reported a moderate to strong anabolic effect, improved appetite, increased vigor, and improved musculature and strength.

These statements reproduce the supplied source material and should not be interpreted as a guarantee of a particular outcome for an individual patient.

Documented Indications

The supplied product information identifies Boldenone Undecylenate 250 as an alternate or adjunctive therapy for the promotion of weight gain following:

• Weight loss and/or muscular atrophy associated with extensive surgery
• Chronic infections
• Long-term hospitalization
• Severe trauma

The source also lists use for increased red blood cell (RBC) production in severe anaemic patients where first-line therapy is contraindicated, and for promotion of increased appetite in patients with limited appetite-related intake.

The supplied documentation states that boldenone should be considered only as adjunctive therapy together with other androgenic medications.

Pharmacokinetic Information

The supplied product description states that Boldenone Undecylenate 250 is designed for slow release of boldenone from the injection site.

Boldenone serum levels are stated in the source to remain elevated for approximately 5–8 days following administration.

No additional pharmacokinetic parameters, such as elimination half-life, clearance or volume of distribution, are supplied.

Adverse Reactions & Safety Information

The supplied product documentation reports the following adverse reactions and potential effects.

Male Reproductive Effects

• Gynecomastia
• Excessive frequency and duration of penile erections
• Oligospermia

Skin & Appendages

• Hirsutism
• Male-pattern baldness
• Acne
• Gynecomastia

Fluid & Electrolyte Disturbances

• Retention of sodium
• Retention of chloride
• Retention of water
• Retention of potassium
• Retention of calcium
• Retention of inorganic phosphates

Gastrointestinal & Hepatic Effects

• Nausea
• Cholestatic jaundice
• Alterations in liver function tests
• Rarely, hepatocellular neoplasms
• Peliosis hepatis
• Hepatic adenomas
• Cholestatic hepatitis

Hematologic Effects

The supplied information reports suppression of clotting factors II, V, VII and X and notes the possibility of bleeding in patients receiving anticoagulant therapy.

Nervous System Effects

Reported effects include:

• Increased or decreased libido
• Headache
• Anxiety
• Depression
• Generalized paresthesia

Other Reported Effects

• Serum lipid changes
• Hypercalcaemia
• Hypertension
• Oedema
• Priapism
• Potentiation of sleep apnea

Contraindications

The supplied product information lists the following contraindications:

• Known hypersensitivity to any ingredient in the product
• Known or suspected carcinoma of the breast, testis or prostate
• Severe heart disease
• Liver disease
• Kidney disease
• History of epilepsy

The source states that products containing androgens should not be used by women because they may cause virilization and fetal harm.

Precautions

The supplied documentation states that caution should be used when administering androgens to patients with a history of myocardial infarction or coronary artery disease because androgens may alter serum cholesterol concentrations.

Additional precautions supplied include:

• Patients receiving oral anticoagulant therapy require close monitoring, particularly when androgen therapy is started or stopped.
• Androgens may alter the metabolism of oral hypoglycaemic agents.
• Androgens may change insulin sensitivity in patients with diabetes mellitus.
• Adjustment of insulin or other hypoglycaemic medication may therefore be required under appropriate medical supervision.

Patient Monitoring

The supplied product information recommends monitoring of:

• Serum cholesterol
• HDL
• LDL
• Triglycerides (TG)
• Haemoglobin
• Haematocrit
• Hepatic function tests, including AST and ALT
• Prostate-specific antigen (PSA)
• Total testosterone
• Free testosterone
• Bioavailable testosterone
• Dihydrotestosterone (DHT)
• Estradiol

The source states that male patients over 40 should undergo a digital rectal examination and PSA evaluation before androgen use.

Periodic prostate evaluations should continue during androgen therapy, particularly in patients experiencing difficulty with urination or changes in voiding habits.

Warning

The supplied product documentation states that human trials have not been conducted and that, in the absence of data on the effects of the drug in human subjects, such use should be on a research basis only under the supervision of a qualified physician.

This warning is reproduced from the supplied source material.

Dosage & Administration

The supplied product information explicitly states:

Dosage has not been established. Use only pursuant to instructions of a qualified physician.

No standardized dosage regimen has been supplied in the source material. No dosage recommendation beyond the manufacturer’s stated information has therefore been added.

Presentation & Storage

Presentation: Boldenone Undecylenate 250 mg/ml, 10 ml multiple-dose vial.

Storage: Store in a cool, dry place between 15–25°C. Protect from light.

Scientific & Regulatory References

No PubMed references, DOI references, clinical-literature citations, manufacturer documents or official regulatory-source links were supplied with the product data.

Accordingly, no external scientific or regulatory references have been added.

The supplied source identifies the market status as Prescription. No specific EU Member State marketing authorization, EU-wide authorization, national authorization number or regulatory approval status was supplied. Therefore, no EU-wide authorization claim is made here.

Pharmaceutical Terms & Compliance

Important: This product information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.

Boldenone Undecylenate 250 is identified in the supplied source as a prescription product. The source also states that human trials have not been conducted and that use described therein should be on a research basis under qualified physician supervision.

Regulatory requirements, authorization status, dispensing conditions and legal availability may differ between European countries. No claim of EU-wide marketing authorization or approval is made based solely on the supplied product information.